Background: The COVID-19 pandemic has created enormous challenges for the clinical management of patients with hematological malignancies (HMs), raising questions about the optimal care of this patient group. Methods: This consensus manuscript aims at discussing clinical evidence and providing expert advice on statements related to the management of HMs in the COVID-19 pandemic. For this purpose, an international consortium was established including a steering committee, which prepared six working packages addressing significant clinical questions from the COVID-19 diagnosis, treatment, and mitigation strategies to specific HMs management in the pandemic. During a virtual consensus meeting, including global experts and lead by the European Society for Medical Oncology and the European Hematology Association, statements were discussed and voted upon. When a consensus could not be reached, the panel revised statements to develop consensual clinical guidance. Results and conclusion: The expert panel agreed on 33 statements, reflecting a consensus, which will guide clinical decision making for patients with hematological neoplasms during the COVID-19 pandemic.

Managing hematological cancer patients during the COVID-19 pandemic: an ESMO-EHA interdisciplinary expert consensus

Passamonti, F.
2022-01-01

Abstract

Background: The COVID-19 pandemic has created enormous challenges for the clinical management of patients with hematological malignancies (HMs), raising questions about the optimal care of this patient group. Methods: This consensus manuscript aims at discussing clinical evidence and providing expert advice on statements related to the management of HMs in the COVID-19 pandemic. For this purpose, an international consortium was established including a steering committee, which prepared six working packages addressing significant clinical questions from the COVID-19 diagnosis, treatment, and mitigation strategies to specific HMs management in the pandemic. During a virtual consensus meeting, including global experts and lead by the European Society for Medical Oncology and the European Hematology Association, statements were discussed and voted upon. When a consensus could not be reached, the panel revised statements to develop consensual clinical guidance. Results and conclusion: The expert panel agreed on 33 statements, reflecting a consensus, which will guide clinical decision making for patients with hematological neoplasms during the COVID-19 pandemic.
2022
consensus manuscript; COVID-19; hematological malignancies
Buske, C.; Dreyling, M.; Alvarez-Larrán, A.; Apperley, J.; Arcaini, L.; Besson, C.; Bullinger, L.; Corradini, P.; Giovanni Della Porta, M.; Dimopoulos, M.; D'Sa, S.; Eich, H. T.; Foà, R.; Ghia, P.; da Silva, M. G.; Gribben, J.; Hajek, R.; Harrison, C.; Heuser, M.; Kiesewetter, B.; Kiladjian, J. J.; Kröger, N.; Moreau, P.; Passweg, J. R.; Peyvandi, F.; Rea, D.; Ribera, J. -M.; Robak, T.; San-Miguel, J. F.; Santini, V.; Sanz, G.; Sonneveld, P.; von Lilienfeld-Toal, M.; Wendtner, C.; Pentheroudakis, G.; Passamonti, F.
File in questo prodotto:
File Dimensione Formato  
1-s2.0-S2059702922000242-main.pdf

accesso aperto

Tipologia: Versione Editoriale (PDF)
Licenza: Creative commons
Dimensione 525.53 kB
Formato Adobe PDF
525.53 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11383/2143455
Citazioni
  • ???jsp.display-item.citation.pmc??? 7
  • Scopus 35
  • ???jsp.display-item.citation.isi??? 29
social impact